Schrödinger, Inc. (Nasdaq: SDGR) today reported that on February 17, 2025, the company granted restricted stock units (RSUs) ...
The following is a summary of “Association between Life’s Essential 8 and Atherogenic Index of Plasma in adults: insights ...
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers Halle (Saale) / Munich, Germany, February 19, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150 ...
Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 dose Results from OVATION 2 Study continue to validate TheraPlas® ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...
Zacks.com on MSN1dOpinion
New Strong Buy Stocks for February 19thList today: GE Aerospace GE: This manufacturer of aircraft engines, components and aircraft mechanical systems has seen the ...
MediShield Life premiums will go up in April 2025, but there will be enhanced coverage limits and new benefits.
In recent months China’s progress in artificial intelligence has stunned the world. A quieter, yet equally significant shift ...
Glenmark Pharmaceuticals reported a net profit of Rs 348 crore for Q3FY25, a significant turnaround from a Rs 351 crore loss ...
IQVIA has seen an increase of 58.97% in its revenues since 2017. Click here to read more about IQV stock and why it is rated ...
The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...
Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback